Researchers reported methods to mass‑produce CAR‑engineered induced natural killer (CAR‑iNK) cells, addressing a key bottleneck for NK‑cell immunotherapies: scalable, cost‑effective manufacturing. The work describes process improvements and bioprocess designs intended to produce clinical‑grade CAR‑iNKs at volumes compatible with broader patient access. The report frames CAR‑iNK as a potential alternative or complement to CAR‑T therapies, with advantages including allogeneic use and potentially lower cytokine toxicity. For readers: CAR‑iNK refers to NK cells engineered with chimeric antigen receptors to target tumor antigens, manufactured from induced or off‑the‑shelf cell sources to enable wider distribution.